Formosa pharmaceuticals makes first shipment of app13007 (clobetasol propionate ophthalmic suspension, 0.05%) to the united states for commercialization

Taipei , sept. 9, 2024 /prnewswire/ -- formosa pharmaceuticals, inc. (hereinafter referred to as "formosa pharma," 6838.tw) announced the successful first shipment to the united states of its new ophthalmic drug, clobetasol propionate ophthalmic suspension, 0.05% (app13007), manufactured by bora pharmaceuticals ophthalmic (hereinafter referred to as "bora," 6472.tw).
APP Ratings Summary
APP Quant Ranking